|
1 radioactive diagnostic agent [epc] |
|
2 positron emitting activity [moa] |
|
3 antiarrhythmic [epc] |
|
4 cytochrome p450 2d6 inhibitor [epc] |
|
5 cytochrome p450 2d6 inhibitors [moa] |
|
6 glp-1 receptor agonist [epc] |
|
7 glucagon-like peptide 1 [chemical/ingredient] |
|
8 glucagon-like peptide-1 (glp-1) agonists [moa] |
|
9 interleukin-17a antagonist [epc] |
|
10 interleukin-17a antagonists [moa] |
|
11 androgen [epc] |
|
12 androgen receptor agonists [moa] |
|
13 androstanes [chemical/ingredient] |
|
14 serotonin reuptake inhibitor [epc] |
|
15 serotonin uptake inhibitors [moa] |
|
16 norepinephrine reuptake inhibitor [epc] |
|
17 norepinephrine uptake inhibitors [moa] |
|
18 atypical antipsychotic [epc] |
|
19 serotonin and norepinephrine reuptake inhibitor [epc] |
|
20 estrogen agonist/antagonist [epc] |
|
21 selective estrogen receptor modulators [moa] |
|
22 phosphodiesterase 5 inhibitor [epc] |
|
23 phosphodiesterase 5 inhibitors [moa] |
|
24 decreased platelet aggregation [pe] |
|
25 p2y12 platelet inhibitor [epc] |
|
26 p2y12 receptor antagonists [moa] |
|
27 nucleic acid synthesis inhibitors [moa] |
|
28 nucleoside metabolic inhibitor [epc] |
|
29 insulin [chemical/ingredient] |
|
30 insulin analog [epc] |
|
31 folate analog metabolic inhibitor [epc] |
|
32 folic acid metabolism inhibitors [moa] |
|
33 vascular endothelial growth factor receptor 2 antagonist [epc] |
|
34 vegfr2 inhibitors [moa] |
|
35 epidermal growth factor receptor antagonist [epc] |
|
36 her1 antagonists [moa] |
|
37 parathyroid hormone [chemical/ingredient] |
|
38 parathyroid hormone analog [epc] |
|
39 insulin [epc] |
|
40 hepatitis c virus ns5a inhibitor [epc] |
|
41 p-glycoprotein inhibitors [moa] |
|
42 organic anion transporting polypeptide 1b1 inhibitors [moa] |
|
43 organic anion transporting polypeptide 1b3 inhibitors [moa] |
|
44 breast cancer resistance protein inhibitors [moa] |
|
45 corticosteroid [epc] |
|
46 corticosteroid hormone receptor agonists [moa] |
|
47 t lymphocyte costimulation activity blockade [pe] |
|
48 selective t cell costimulation blocker [epc] |
|
49 cd80-directed antibody interactions [moa] |
|
50 cd86-directed antibody interactions [moa] |
|
51 kinase inhibitor [epc] |
|
52 protein kinase inhibitors [moa] |
|
53 cytochrome p450 3a4 inhibitors [moa] |
|
54 antimetabolite [epc] |
|
55 urea [chemical/ingredient] |
|
56 factor xa inhibitor [epc] |
|
57 factor xa inhibitors [moa] |
|
58 hepatitis b virus nucleoside analog reverse transcriptase inhibitor [epc] |
|
59 nucleoside analog [chemical/ingredient] |
|
60 nucleoside reverse transcriptase inhibitors [moa] |
|
61 human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor [epc] |
|
62 decreased cytokine activity [pe] |
|
63 selective t cell costimulation modulator [epc] |
|
64 recombinant fusion proteins [chemical/ingredient] |
|
65 monobactam antibacterial [epc] |
|
66 monobactams [chemical/ingredient] |
|
67 slamf7-directed immunostimulatory antibody [epc] |
|
68 slamf7-directed antibody interactions [moa] |
|
69 antibodies |
|
70 monoclonal [chemical/ingredient] |
|
71 ctla-4-directed blocking antibody [epc] |
|
72 ctla-4-directed antibody interactions [moa] |
|
73 increased t lymphocyte activation [pe] |
|
74 hiv protease inhibitors [moa] |
|
75 protease inhibitor [epc] |
|
76 ugt1a1 inhibitors [moa] |
|
77 udp glucuronosyltransferases inhibitors [moa] |
|
78 cytochrome p450 3a inhibitors [moa] |
|
79 cytochrome p450 2c8 inhibitors [moa] |
|
80 cytochrome p450 3a inhibitor [epc] |
|
81 programmed death receptor-1 blocking antibody [epc] |
|
82 programmed death receptor-1-directed antibody interactions [moa] |
|
83 hmg-coa reductase inhibitor [epc] |
|
84 hydroxymethylglutaryl-coa reductase inhibitors [moa] |
|
85 cytomegalovirus nucleoside analog dna polymerase inhibitor [epc] |
|
86 dna polymerase inhibitors [moa] |
|
87 nucleoside analog antiviral [epc] |
|
88 benzodiazepine [epc] |
|
89 benzodiazepines [chemical/ingredient] |
|
90 bisphosphonate [epc] |
|
91 diphosphonates [chemical/ingredient] |
|
92 intestinal lipase inhibitor [epc] |
|
93 lipase inhibitors [moa] |
|
94 antimetabolite immunosuppressant [epc] |
|
95 interferon alpha [epc] |
|
96 peginterferon alfa-2a [chemical/ingredient] |
|
97 erythropoiesis-stimulating agent [epc] |
|
98 erythropoietin [chemical/ingredient] |
|
99 increased erythroid cell production [pe] |
|
100 cyclooxygenase inhibitors [moa] |
|
101 nonsteroidal anti-inflammatory compounds [chemical/ingredient] |
|
102 nonsteroidal anti-inflammatory drug [epc] |
|
103 inactivated pneumococcal vaccine [epc] |
|
104 actively acquired immunity [pe] |
|
105 vaccines |
|
106 inactivated [chemical/ingredient] |
|
107 pneumococcal vaccines [chemical/ingredient] |
|
108 conjugate [chemical/ingredient] |
|
109 orexin receptor antagonist [epc] |
|
110 orexin receptor antagonists [moa] |
|
111 angiotensin converting enzyme inhibitor [epc] |
|
112 angiotensin-converting enzyme inhibitors [moa] |
|
113 antiparasitic [epc] |
|
114 pediculicide [epc] |
|
115 5-alpha reductase inhibitor [epc] |
|
116 5-alpha reductase inhibitors [moa] |
|
117 dipeptidyl peptidase 4 inhibitor [epc] |
|
118 dipeptidyl peptidase 4 inhibitors [moa] |
|
119 biguanide [epc] |
|
120 biguanides [chemical/ingredient] |
|
121 hiv integrase inhibitors [moa] |
|
122 human immunodeficiency virus integrase strand transfer inhibitor [epc] |
|
123 serotonin 1b receptor agonists [moa] |
|
124 serotonin 1d receptor agonists [moa] |
|
125 serotonin-1b and serotonin-1d receptor agonist [epc] |
|
126 vitamin d [chemical/ingredient] |
|
127 vitamin d [epc] |
|
128 protease-activated receptor-1 antagonist [epc] |
|
129 protease-activated receptor-1 antagonists [moa] |
|
130 neurokinin 1 antagonists [moa] |
|
131 substance p/neurokinin-1 receptor antagonist [epc] |
|
132 cytochrome p450 2c9 inducers [moa] |
|
133 cytochrome p450 3a4 inducers [moa] |
|
134 histone deacetylase inhibitor [epc] |
|
135 histone deacetylase inhibitors [moa] |
|
136 angiotensin 2 receptor antagonists [moa] |
|
137 angiotensin 2 receptor blocker [epc] |
|
138 increased diuresis [pe] |
|
139 thiazide diuretic [epc] |
|
140 thiazides [chemical/ingredient] |
|
141 leukotriene receptor antagonist [epc] |
|
142 leukotriene receptor antagonists [moa] |
|
143 hcv ns3/4a protease inhibitors [moa] |
|
144 hepatitis c virus ns3/4a protease inhibitor [epc] |
|
145 dipeptidase inhibitors [moa] |
|
146 renal dehydropeptidase inhibitor [epc] |
|
147 carbapenems [chemical/ingredient] |
|
148 penem antibacterial [epc] |
|
149 carbonic anhydrase inhibitor [epc] |
|
150 carbonic anhydrase inhibitors [moa] |
|
151 echinocandin antifungal [epc] |
|
152 lipopeptides [chemical/ingredient] |
|
153 aromatic amino acid [epc] |
|
154 amino acids |
|
155 aromatic [chemical/ingredient] |
|
156 inactivated human papillomavirus vaccine [epc] |
|
157 papillomavirus vaccines [chemical/ingredient] |
|
158 live rotavirus vaccine [epc] |
|
159 rotavirus vaccines [chemical/ingredient] |
|
160 live |
|
161 unattenuated [chemical/ingredient] |
|
162 inactivated hepatitis b virus vaccine [epc] |
|
163 hepatitis b vaccines [chemical/ingredient] |
|
164 inactivated hepatitis a virus vaccine [epc] |
|
165 hepatitis a vaccines [chemical/ingredient] |
|
166 live attenuated measles virus vaccine [epc] |
|
167 attenuated [chemical/ingredient] |
|
168 measles vaccine [chemical/ingredient] |
|
169 live attenuated mumps virus vaccine [epc] |
|
170 mumps vaccine [chemical/ingredient] |
|
171 live attenuated rubella virus vaccine [epc] |
|
172 rubella vaccine [chemical/ingredient] |
|
173 live attenuated varicella zoster virus vaccine [epc] |
|
174 chickenpox vaccine [chemical/ingredient] |
|
175 live attenuated herpes zoster virus vaccine [epc] |
|
176 herpes zoster vaccine [chemical/ingredient] |
|
177 standardized pollen allergenic extract [epc] |
|
178 increased histamine release [pe] |
|
179 cell-mediated immunity [pe] |
|
180 increased igg production [pe] |
|
181 pollen [chemical/ingredient] |
|
182 allergens [chemical/ingredient] |
|
183 tumor necrosis factor blocker [epc] |
|
184 tumor necrosis factor receptor blocking activity [moa] |
|
185 inactivated haemophilus influenzae b vaccine [epc] |
|
186 haemophilus vaccines [chemical/ingredient] |
|
187 gamma-cyclodextrins [chemical/ingredient] |
|
188 adrenergic alpha-antagonists [moa] |
|
189 adrenergic beta1-antagonists [moa] |
|
190 adrenergic beta2-antagonists [moa] |
|
191 alpha-adrenergic blocker [epc] |
|
192 beta-adrenergic blocker [epc] |
|
193 decreased renal k+ excretion [pe] |
|
194 potassium-sparing diuretic [epc] |
|
195 topoisomerase inhibitor [epc] |
|
196 topoisomerase inhibitors [moa] |
|
197 anti-coagulant [epc] |
|
198 direct thrombin inhibitor [epc] |
|
199 thrombin inhibitors [moa] |
|
200 increased megakaryocyte maturation [pe] |
|
201 increased platelet production [pe] |
|
202 thrombopoietin receptor agonist [epc] |
|
203 thrombopoietin receptor agonists [moa] |
|
204 ugt1a3 inhibitors [moa] |
|
205 ugt1a4 inhibitors [moa] |
|
206 ugt1a6 inhibitors [moa] |
|
207 ugt1a9 inhibitors [moa] |
|
208 ugt2b7 inhibitors [moa] |
|
209 ugt2b15 inhibitors [moa] |
|
210 dopamine agonists [moa] |
|
211 nonergot dopamine agonist [epc] |
|
212 vinca alkaloid [epc] |
|
213 vinca alkaloids [chemical/ingredient] |
|
214 proton pump inhibitor [epc] |
|
215 proton pump inhibitors [moa] |
|
216 decreased immunologic activity [pe] |
|
217 mtor inhibitor immunosuppressant [epc] |
|
218 mtor inhibitors [moa] |
|
219 estrogen [epc] |
|
220 estrogen receptor agonists [moa] |
|
221 estrogens |
|
222 conjugated (usp) [chemical/ingredient] |
|
223 antimycobacterial [epc] |
|
224 cd33-directed cytotoxin [epc] |
|
225 tetracycline-class antibacterial [epc] |
|
226 tetracyclines [chemical/ingredient] |
|
227 progesterone congeners [chemical/ingredient] |
|
228 progestin [epc] |
|
229 decreased sebaceous gland activity [pe] |
|
230 lincosamide antibacterial [epc] |
|
231 lincosamides [chemical/ingredient] |
|
232 decreased cell wall synthesis & repair [pe] |
|
233 bile acid sequestrant [epc] |
|
234 bile-acid binding activity [moa] |
|
235 estradiol congeners [chemical/ingredient] |
|
236 sulfonylurea [epc] |
|
237 sulfonylurea compounds [chemical/ingredient] |
|
238 prostaglandin analog [epc] |
|
239 prostaglandins [chemical/ingredient] |
|
240 genitourinary arterial vasodilation [pe] |
|
241 prostaglandin e1 agonist [epc] |
|
242 prostaglandin receptor agonists [moa] |
|
243 venous vasodilation [pe] |
|
244 cholinergic muscarinic antagonist [epc] |
|
245 cholinergic muscarinic antagonists [moa] |
|
246 oxazolidinone antibacterial [epc] |
|
247 oxazolidinones [chemical/ingredient] |
|
248 alpha glucosidase inhibitors [moa] |
|
249 alpha-glucosidase inhibitor [epc] |
|
250 anthracycline topoisomerase inhibitor [epc] |
|
251 anthracyclines [chemical/ingredient] |
|
252 cholinergic nicotinic agonist [epc] |
|
253 nicotine [chemical/ingredient] |
|
254 immunoglobulin g [epc] |
|
255 lymphocyte function alteration [pe] |
|
256 increased t lymphocyte destruction [pe] |
|
257 antibody-surface protein interactions [moa] |
|
258 immunoglobulins [chemical/ingredient] |
|
259 aromatase inhibitor [epc] |
|
260 aromatase inhibitors [moa] |
|
261 aminosalicylate [epc] |
|
262 aminosalicylic acids [chemical/ingredient] |
|
263 alkylating activity [moa] |
|
264 alkylating drug [epc] |
|
265 estradiol [chemical/ingredient] |
|
266 nitrogen mustard compounds [chemical/ingredient] |
|
267 antifibrinolytic agent [epc] |
|
268 decreased fibrinolysis [pe] |
|
269 rifamycin antimycobacterial [epc] |
|
270 rifamycins [chemical/ingredient] |
|
271 cytoprotective agent [epc] |
|
272 radiographic contrast agent [epc] |
|
273 x-ray contrast activity [moa] |
|
274 gadolinium-based contrast agent [epc] |
|
275 magnetic resonance contrast activity [moa] |
|
276 osmotic laxative [epc] |
|
277 increased large intestinal motility [pe] |
|
278 inhibition large intestine fluid/electrolyte absorption [pe] |
|
279 osmotic activity [moa] |
|
280 retinoid [epc] |
|
281 retinoids [chemical/ingredient] |
|
282 aminoglycoside antibacterial [epc] |
|
283 aminoglycosides [chemical/ingredient] |
|
284 sulfonamide antibacterial [epc] |
|
285 sulfonamides [chemical/ingredient] |
|
286 acetylcholine release inhibitor [epc] |
|
287 acetylcholine release inhibitors [moa] |
|
288 cyclooxygenase inhibitor [epc] |
|
289 quinolone antimicrobial [epc] |
|
290 quinolones [chemical/ingredient] |
|
291 sulfone [epc] |
|
292 sulfones [chemical/ingredient] |
|
293 histamine h1 receptor antagonists [moa] |
|
294 histamine-1 receptor antagonist [epc] |
|
295 adrenergic beta-antagonists [moa] |
|
296 antiprotozoal [epc] |
|
297 decarboxylase inhibitor [epc] |
|
298 decarboxylase inhibitors [moa] |
|
299 vasoconstrictor [epc] |
|
300 vasoconstriction [pe] |
|
301 increased sympathetic activity [pe] |
|
302 imidazolines [chemical/ingredient] |
|
303 calcineurin inhibitor immunosuppressant [epc] |
|
304 calcineurin inhibitors [moa] |
|
305 inhibit ovum fertilization [pe] |
|
306 progestin-containing intrauterine device [epc] |
|
307 nitroimidazole antimicrobial [epc] |
|
308 nitroimidazoles [chemical/ingredient] |
|
309 opioid agonist [epc] |
|
310 opioid agonists [moa] |
|
311 barbiturate [epc] |
|
312 barbiturates [chemical/ingredient] |
|
313 decreased prostaglandin production [pe] |
|
314 platelet aggregation inhibitor [epc] |
|
315 central nervous system stimulant [epc] |
|
316 central nervous system stimulation [pe] |
|
317 methylxanthine [epc] |
|
318 xanthines [chemical/ingredient] |
|
319 full opioid agonists [moa] |
|
320 polymyxin-class antibacterial [epc] |
|
321 polymyxins [chemical/ingredient] |
|
322 dihydrofolate reductase inhibitor antibacterial [epc] |
|
323 dihydrofolate reductase inhibitors [moa] |
|
324 organic cation transporter 2 inhibitors [moa] |
|
325 decreased protein synthesis [pe] |
|
326 decreased histamine release [pe] |
|
327 mast cell stabilizer [epc] |
|
328 adrenergic alpha-agonists [moa] |
|
329 alpha-adrenergic agonist [epc] |
|
330 adrenergic agonists [moa] |
|
331 adrenergic receptor agonist [epc] |
|
332 histamine-1 receptor inhibitor [epc] |
|
333 ergocalciferols [chemical/ingredient] |
|
334 provitamin d2 compound [epc] |
|
335 platinum-based drug [epc] |
|
336 platinum-containing compounds [chemical/ingredient] |
|
337 antiseptic [epc] |
|
338 antirheumatic agent [epc] |
|
339 antimalarial [epc] |
|
340 iron [chemical/ingredient] |
|
341 parenteral iron replacement [epc] |
|
342 phosphate binder [epc] |
|
343 phosphate chelating activity [moa] |
|
344 gamma-aminobutyric acid-ergic agonist [epc] |
|
345 gaba a agonists [moa] |
|
346 pyridines [chemical/ingredient] |
|
347 central nervous system depression [pe] |
|
348 aminoketone [epc] |
|
349 dopamine uptake inhibitors [moa] |
|
350 increased dopamine activity [pe] |
|
351 increased norepinephrine activity [pe] |
|
352 granulocyte colony-stimulating factor [chemical/ingredient] |
|
353 granulocyte-macrophage colony-stimulating factor [chemical/ingredient] |
|
354 increased myeloid cell production [pe] |
|
355 leukocyte growth factor [epc] |
|
356 hematopoietic stem cell mobilizer [epc] |
|
357 increased hematopoietic stem cell mobilization [pe] |
|
358 pcsk9 inhibitor [epc] |
|
359 pcsk9 inhibitors [moa] |
|
360 interleukin 6 receptor antagonists [moa] |
|
361 interleukin-6 receptor antagonist [epc] |
|
362 antidiarrheal [epc] |
|
363 anticholinergic [epc] |
|
364 cholinergic antagonists [moa] |
|
365 gonadotropin releasing hormone receptor agonist [epc] |
|
366 gonadotropin releasing hormone receptor agonists [moa] |
|
367 aldosterone antagonist [epc] |
|
368 aldosterone antagonists [moa] |
|
369 prostaglandin e1 analog [epc] |
|
370 prostaglandins e |
|
371 synthetic [chemical/ingredient] |
|
372 calcium channel antagonists [moa] |
|
373 calcium channel blocker [epc] |
|
374 rna synthetase inhibitor antibacterial [epc] |
|
375 rna synthetase inhibitors [moa] |
|
376 progesterone [chemical/ingredient] |
|
377 progesterone [epc] |
|
378 vitamin b6 analog [epc] |
|
379 vitamin b 6 [chemical/ingredient] |
|
380 analogs/derivatives [chemical/ingredient] |
|
381 vitamin b 12 [chemical/ingredient] |
|
382 vitamin b12 [epc] |
|
383 blood coagulation factor [epc] |
|
384 increased coagulation factor activity [pe] |
|
385 calcium [chemical/ingredient] |
|
386 cations |
|
387 divalent [chemical/ingredient] |
|
388 anti-epileptic agent [epc] |
|
389 decreased central nervous system disorganized electrical activity [pe] |
|
390 cannabinoid [epc] |
|
391 cannabinoids [chemical/ingredient] |
|
392 centrally-mediated muscle relaxation [pe] |
|
393 muscle relaxant [epc] |
|
394 increased diuresis at loop of henle [pe] |
|
395 loop diuretic [epc] |
|
396 calcium [epc] |
|
397 oxidation-reduction agent [epc] |
|
398 oxidation-reduction activity [moa] |
|
399 stimulation large intestine fluid/electrolyte secretion [pe] |
|
400 potassium compounds [chemical/ingredient] |
|
401 potassium salt [epc] |
|
402 penicillin-class antibacterial [epc] |
|
403 penicillins [chemical/ingredient] |
|
404 beta lactamase inhibitors [moa] |
|
405 beta lactamase inhibitor [epc] |
|
406 antiemetic [epc] |
|
407 emesis suppression [pe] |
|
408 azole antifungal [epc] |
|
409 azoles [chemical/ingredient] |
|
410 cytochrome p450 2c19 inhibitors [moa] |
|
411 cytochrome p450 2c9 inhibitors [moa] |
|
412 decreased gnrh secretion [pe] |
|
413 gonadotropin releasing hormone antagonist [epc] |
|
414 gonadotropin releasing hormone receptor antagonists [moa] |
|
415 gonadotropin [epc] |
|
416 gonadotropins [chemical/ingredient] |
|
417 neuromuscular nondepolarizing blockade [pe] |
|
418 nondepolarizing neuromuscular blocker [epc] |
|
419 live attenuated bacillus calmette-guerin vaccine [epc] |
|
420 bcg vaccine [chemical/ingredient] |
|
421 live attenuated bacillus calmette-guerin immunotherapy [epc] |
|
422 increased macrophage proliferation [pe] |
|
423 increased immunologically active molecule activity [pe] |
|
424 factor viii activator [epc] |
|
425 increased coagulation factor viii activity [pe] |
|
426 increased coagulation factor viii concentration [pe] |
|
427 vasopressin analog [epc] |
|
428 vasopressins [chemical/ingredient] |
|
429 human serum albumin [epc] |
|
430 increased intravascular volume [pe] |
|
431 increased oncotic pressure [pe] |
|
432 serum albumin [chemical/ingredient] |
|
433 cholecalciferol [chemical/ingredient] |
|
434 vitamin d3 analog [epc] |
|
435 mood stabilizer [epc] |
|
436 phosphodiesterase 3 inhibitor [epc] |
|
437 phosphodiesterase 3 inhibitors [moa] |
|
438 macrolide antimicrobial [epc] |
|
439 macrolides [chemical/ingredient] |
|
440 cardiac glycoside [epc] |
|
441 cardiac glycosides [chemical/ingredient] |
|
442 serotonin 3 receptor antagonists [moa] |
|
443 serotonin-3 receptor antagonist [epc] |
|
444 gamma-aminobutyric acid a receptor agonist [epc] |
|
445 cholinesterase inhibitor [epc] |
|
446 cholinesterase inhibitors [moa] |
|
447 dihydropyridine calcium channel blocker [epc] |
|
448 dihydropyridines [chemical/ingredient] |
|
449 herpes simplex virus nucleoside analog dna polymerase inhibitor [epc] |
|
450 herpes zoster virus nucleoside analog dna polymerase inhibitor [epc] |
|
451 herpesvirus nucleoside analog dna polymerase inhibitor [epc] |
|
452 partial opioid agonist [epc] |
|
453 partial opioid agonists [moa] |
|
454 opioid antagonist [epc] |
|
455 opioid antagonists [moa] |
|
456 tricyclic antidepressant [epc] |
|
457 cholinergic muscarinic agonists [moa] |
|
458 cholinergic receptor agonist [epc] |
|
459 vitamin d2 analog [epc] |
|
460 acetyl aldehyde dehydrogenase inhibitors [moa] |
|
461 aldehyde dehydrogenase inhibitor [epc] |
|
462 amphetamine anorectic [epc] |
|
463 amphetamines [chemical/ingredient] |
|
464 appetite suppression [pe] |
|
465 human immunodeficiency virus 1 non-nucleoside analog reverse transcriptase inhibitor [epc] |
|
466 non-nucleoside analog [chemical/ingredient] |
|
467 non-nucleoside reverse transcriptase inhibitors [moa] |
|
468 cytochrome p450 3a inducers [moa] |
|
469 cytochrome p450 2b6 inducers [moa] |
|
470 amide local anesthetic [epc] |
|
471 amides [chemical/ingredient] |
|
472 local anesthesia [pe] |
|
473 competitive opioid antagonists [moa] |
|
474 opioid agonist/antagonist [epc] |
|
475 acidifying activity [moa] |
|
476 folate analog [epc] |
|
477 folic acid [chemical/ingredient] |
|
478 vitamin k antagonist [epc] |
|
479 vitamin k inhibitors [moa] |
|
480 cholinergic agonists [moa] |
|
481 diagnostic dye [epc] |
|
482 dyes [moa] |
|
483 alpha-1 adrenergic agonist [epc] |
|
484 adrenergic alpha1-agonists [moa] |
|
485 polyene antimicrobial [epc] |
|
486 polyenes [chemical/ingredient] |
|
487 ester local anesthetic [epc] |
|
488 esters [chemical/ingredient] |
|
489 calculi dissolution agent [epc] |
|
490 magnesium ion exchange activity [moa] |
|
491 inhibition small intestine fluid/electrolyte absorption [pe] |
|
492 rifamycin antibacterial [epc] |
|
493 general anesthesia [pe] |
|
494 general anesthetic [epc] |
|
495 heparin [chemical/ingredient] |
|
496 unfractionated heparin [epc] |
|
497 microtubule inhibition [pe] |
|
498 microtubule inhibitor [epc] |
|
499 purine antimetabolite [epc] |
|
500 benzodiazepine antagonist [epc] |
|
501 hydrolytic lysosomal glucocerebroside-specific enzyme [epc] |
|
502 glucosylceramidase [chemical/ingredient] |
|
503 typical antipsychotic [epc] |
|
504 histamine h2 receptor antagonists [moa] |
|
505 histamine-2 receptor antagonist [epc] |
|
506 decreased tracheobronchial stretch receptor activity [pe] |
|
507 non-narcotic antitussive [epc] |
|
508 receptor tyrosine kinase inhibitors [moa] |
|
509 kinase inhibitors [moa] |
|
510 heparin |
|
511 low-molecular-weight [chemical/ingredient] |
|
512 low molecular weight heparin [epc] |
|
513 partial cholinergic nicotinic agonist [epc] |
|
514 partial cholinergic nicotinic agonists [moa] |
|
515 janus kinase inhibitor [epc] |
|
516 janus kinase inhibitors [moa] |
|
517 ccr5 co-receptor antagonist [epc] |
|
518 chemokine co-receptor 5 antagonists [moa] |
|
519 glycopeptide antibacterial [epc] |
|
520 glycopeptides [chemical/ingredient] |
|
521 antihistamine [epc] |
|
522 histamine receptor antagonists [moa] |
|
523 cytochrome p450 1a2 inducers [moa] |
|
524 cytochrome p450 2c8 inducers [moa] |
|
525 cytochrome p450 2c19 inducers [moa] |
|
526 cytochrome p450 2d6 inducers [moa] |
|
527 cytochrome p450 2b6 inhibitors [moa] |
|
528 organic cation transporter 1 inhibitors [moa] |
|
529 monoamine oxidase inhibitor [epc] |
|
530 monoamine oxidase inhibitors [moa] |
|
531 nitrate vasodilator [epc] |
|
532 nitrates [chemical/ingredient] |
|
533 vasodilation [pe] |
|
534 peroxisome proliferator receptor alpha agonist [epc] |
|
535 peroxisome proliferator-activated receptor alpha agonists [moa] |
|
536 ppar alpha [chemical/ingredient] |
|
537 interleukin 2 receptor antagonists [moa] |
|
538 interleukin 2 receptor-directed antibody interactions [moa] |
|
539 interleukin-2 receptor blocking antibody [epc] |
|
540 udp glucuronosyltransferases inducers [moa] |
|
541 bcl-2 inhibitor [epc] |
|
542 increased cellular death [pe] |
|
543 alveolar surface tension reduction [pe] |
|
544 surfactant [epc] |
|
545 surfactant activity [moa] |
|
546 nicotinic acid [epc] |
|
547 nicotinic acids [chemical/ingredient] |
|
548 l-thyroxine [epc] |
|
549 thyroxine [chemical/ingredient] |
|
550 benzothiazole [epc] |
|
551 benzothiazoles [chemical/ingredient] |
|
552 ammonium ion binding activity [moa] |
|
553 nitrogen binding agent [epc] |
|
554 allylamine [chemical/ingredient] |
|
555 allylamine antifungal [epc] |
|
556 somatostatin analog [epc] |
|
557 somatostatin receptor agonists [moa] |
|
558 catechol o-methyltransferase inhibitors [moa] |
|
559 catechol-o-methyltransferase inhibitor [epc] |
|
560 glinide [epc] |
|
561 potassium channel antagonists [moa] |
|
562 decreased blood pressure [pe] |
|
563 iron chelating activity [moa] |
|
564 iron chelator [epc] |
|
565 cytochrome p450 1a2 inhibitors [moa] |
|
566 renin inhibitor [epc] |
|
567 renin inhibitors [moa] |
|
568 sphingosine 1-phosphate receptor modulators [moa] |
|
569 sphingosine 1-phosphate receptor modulator [epc] |
|
570 adrenergic beta2-agonists [moa] |
|
571 beta2-adrenergic agonist [epc] |
|
572 tyrosine kinase inhibitors [moa] |
|
573 hedgehog pathway inhibitor [epc] |
|
574 smoothened receptor antagonists [moa] |
|
575 neprilysin inhibitor [epc] |
|
576 neprilysin inhibitors [moa] |
|
577 cd20-directed cytolytic antibody [epc] |
|
578 cd20-directed antibody interactions [moa] |
|
579 organic anion transporter 1 inhibitors [moa] |
|
580 organic anion transporter 3 inhibitors [moa] |
|
581 cytochrome p450 3a5 inhibitors [moa] |
|
582 acetylcholine releasing agent [epc] |
|
583 increased acetylcholine activity [pe] |
|
584 interferon alfa-2b [chemical/ingredient] |
|
585 interferon-alpha [chemical/ingredient] |
|
586 androgen receptor antagonists [moa] |
|
587 androgen receptor inhibitor [epc] |
|
588 polyene antifungal [epc] |
|
589 cardiac rhythm alteration [pe] |
|
590 cephalosporin antibacterial [epc] |
|
591 cephalosporins [chemical/ingredient] |
|
592 peroxisome proliferator receptor gamma agonist [epc] |
|
593 peroxisome proliferator-activated receptor activity [moa] |
|
594 ppar gamma [chemical/ingredient] |
|
595 thiazolidinedione [epc] |
|
596 thiazolidinediones [chemical/ingredient] |
|
597 sympathomimetic amine anorectic [epc] |
|
598 nitrofuran antibacterial [epc] |
|
599 nitrofurans [chemical/ingredient] |
|
600 dopamine d2 antagonists [moa] |
|
601 dopamine-2 receptor antagonist [epc] |
|
602 aluminum complex [epc] |
|
603 organometallic compounds [chemical/ingredient] |
|
604 adrenergic alpha2-agonists [moa] |
|
605 central alpha-2 adrenergic agonist [epc] |
|
606 tetracycline-class drug [epc] |
|
607 blood viscosity reducer [epc] |
|
608 hematologic activity alteration [pe] |
|
609 fatty acids |
|
610 omega-3 [chemical/ingredient] |
|
611 omega-3 fatty acid [epc] |
|
612 ergolines [chemical/ingredient] |
|
613 ergot derivative [epc] |
|
614 inhibition gastric acid secretion [pe] |
|
615 phenothiazine [epc] |
|
616 phenothiazines [chemical/ingredient] |
|
617 decreased cholesterol absorption [pe] |
|
618 dietary cholesterol absorption inhibitor [epc] |
|
619 vitamin d analog [epc] |
|
620 bile acid [epc] |
|
621 bile acids and salts [chemical/ingredient] |
|
622 adrenergic beta-agonists [moa] |
|
623 beta-adrenergic agonist [epc] |
|
624 catecholamine [epc] |
|
625 catecholamines [chemical/ingredient] |
|
626 influenza a m2 protein inhibitor [epc] |
|
627 m2 protein inhibitors [moa] |
|
628 decreased striated muscle contraction [pe] |
|
629 decreased striated muscle tone [pe] |
|
630 skeletal muscle relaxant [epc] |
|
631 decreased cell wall integrity [pe] |
|
632 decreased coagulation factor activity [pe] |
|
633 calcium chelating activity [moa] |
|
634 sulfonamide antimicrobial [epc] |
|
635 thyroid hormone synthesis inhibitor [epc] |
|
636 thyroid hormone synthesis inhibitors [moa] |
|
637 ergotamine derivative [epc] |
|
638 ergotamines [chemical/ingredient] |
|
639 p-glycoprotein interactions [moa] |
|
640 xanthine oxidase inhibitor [epc] |
|
641 xanthine oxidase inhibitors [moa] |
|
642 purines [chemical/ingredient] |
|
643 increased uterine smooth muscle contraction or tone [pe] |
|
644 oxytocic [epc] |
|
645 oxytocin [chemical/ingredient] |
|
646 sympathomimetic-like agent [epc] |
|
647 macrolide [epc] |
|
648 decreased dna replication [pe] |
|
649 decreased rna replication [pe] |
|
650 protein synthesis inhibitors [moa] |
|
651 increased cytokine activity [pe] |
|
652 increased cytokine production [pe] |
|
653 interferon inducers [moa] |
|
654 recombinant human growth hormone [epc] |
|
655 recombinant human growth hormones [chemical/ingredient] |
|
656 gaba b agonists [moa] |
|
657 decreased platelet production [pe] |
|
658 platelet-reducing agent [epc] |
|
659 prostacycline vasodilator [epc] |
|
660 prostaglandins i [chemical/ingredient] |
|
661 neuraminidase inhibitor [epc] |
|
662 neuraminidase inhibitors [moa] |
|
663 potassium channel openers [moa] |
|
664 potassium channel opener [epc] |
|
665 interleukin-5 antagonist [epc] |
|
666 interleukin-5 antagonists [moa] |
|
667 urease inhibitor [epc] |
|
668 urease inhibitors [moa] |
|
669 cystine disulfide reduction [moa] |
|
670 n-substituted glycines [chemical/ingredient] |
|
671 reducing and complexing thiol [epc] |
|
672 thiazide-like diuretic [epc] |
|
673 l-triiodothyronine [epc] |
|
674 triiodothyronine [chemical/ingredient] |
|
675 dihydrofolate reductase inhibitor antimalarial [epc] |
|
676 increased prothrombin activity [pe] |
|
677 reversed anticoagulation activity [pe] |
|
678 vitamin k [chemical/ingredient] |
|
679 vitamin k [epc] |
|
680 warfarin reversal agent [epc] |
|
681 phenylalanine hydroxylase activators [moa] |
|
682 interleukin-17 receptor a antagonist [epc] |
|
683 interleukin 17 receptor a antagonists [moa] |
|
684 monoamine oxidase type b inhibitor [epc] |
|
685 monoamine oxidase-b inhibitors [moa] |
|
686 photoabsorption [moa] |
|
687 photoactivated radical generator [epc] |
|
688 photosensitizing activity [pe] |
|
689 psoralen [epc] |
|
690 psoralens [chemical/ingredient] |
|
691 metal chelating activity [moa] |
|
692 metal chelator [epc] |
|
693 nucleoside analog antifungal [epc] |
|
694 decreased parasympathetic acetylcholine activity [pe] |
|
695 gi motility alteration [pe] |
|
696 digestive/gi system activity alteration [pe] |
|
697 vasodilator [epc] |
|
698 photoenhancer [epc] |
|
699 calcitonin [chemical/ingredient] |
|
700 calcitonin [epc] |
|
701 non-standardized plant allergenic extract [epc] |
|
702 non-standardized food allergenic extract [epc] |
|
703 dietary proteins [chemical/ingredient] |
|
704 plant proteins [chemical/ingredient] |
|
705 food additives [chemical/ingredient] |
|
706 non-standardized chemical allergen [epc] |
|
707 glycerol [chemical/ingredient] |
|
708 amino acid [epc] |
|
709 amino acids [chemical/ingredient] |
|
710 plasma volume expander [epc] |
|
711 starch [chemical/ingredient] |
|
712 osmotic diuretic [epc] |
|
713 lipid emulsion [epc] |
|
714 lipids [chemical/ingredient] |
|
715 non-standardized pollen allergenic extract [epc] |
|
716 standardized animal skin allergenic extract [epc] |
|
717 fur [chemical/ingredient] |
|
718 standardized insect allergenic extract [epc] |
|
719 antigens |
|
720 dermatophagoides [chemical/ingredient] |
|
721 insect proteins [chemical/ingredient] |
|
722 non-standardized animal skin allergenic extract [epc] |
|
723 cells |
|
724 epidermal [chemical/ingredient] |
|
725 non-standardized plant fiber allergenic extract [epc] |
|
726 seed storage proteins [chemical/ingredient] |
|
727 meat proteins [chemical/ingredient] |
|
728 non-standardized insect allergenic extract [epc] |
|
729 non-standardized insect venom allergenic extract [epc] |
|
730 ant venoms [chemical/ingredient] |
|
731 non-standardized feather allergenic extract [epc] |
|
732 feathers [chemical/ingredient] |
|
733 non-standardized fungal allergenic extract [epc] |
|
734 fungal proteins [chemical/ingredient] |
|
735 standardized animal hair allergenic extract [epc] |
|
736 dander [chemical/ingredient] |
|
737 salivary proteins and peptides [chemical/ingredient] |
|
738 non-standardized house dust allergenic extract [epc] |
|
739 house dust [chemical/ingredient] |
|
740 nut proteins [chemical/ingredient] |
|
741 fruit proteins [chemical/ingredient] |
|
742 vegetable proteins [chemical/ingredient] |
|
743 grain proteins [chemical/ingredient] |
|
744 caseins [chemical/ingredient] |
|
745 poultry proteins [chemical/ingredient] |
|
746 shellfish proteins [chemical/ingredient] |
|
747 fish proteins |
|
748 dietary [chemical/ingredient] |
|
749 egg proteins |
|
750 milk proteins [chemical/ingredient] |
|
751 radiopharmaceutical activity [moa] |
|
752 cholecystokinin [chemical/ingredient] |
|
753 cholecystokinin analog [epc] |
|
754 paramagnetic contrast agent [epc] |
|
755 digoxin binding activity [moa] |
|
756 depigmenting activity [pe] |
|
757 melanin synthesis inhibitor [epc] |
|
758 melanin synthesis inhibitors [moa] |
|
759 phosphodiesterase 4 inhibitor [epc] |
|
760 phosphodiesterase 4 inhibitors [moa] |
|
761 poly(adp-ribose) polymerase inhibitor [epc] |
|
762 poly(adp-ribose) polymerase inhibitors [moa] |
|
763 estrogen receptor antagonist [epc] |
|
764 estrogen receptor antagonists [moa] |
|
765 urate transporter 1 inhibitor [epc] |
|
766 urate transporter 1 inhibitors [moa] |
|
767 sodium-glucose cotransporter 2 inhibitor [epc] |
|
768 sodium-glucose transporter 2 inhibitors [moa] |
|
769 amylin agonists [moa] |
|
770 amylin analog [epc] |
|
771 standardized chemical allergen [epc] |
|
772 irrigation [moa] |
|
773 human blood coagulation factor [epc] |
|
774 increased coagulation activity [pe] |
|
775 blood coagulation factors [chemical/ingredient] |
|
776 nmda receptor antagonists [moa] |
|
777 n-methyl-d-aspartate receptor antagonist [epc] |
|
778 p-glycoprotein inducers [moa] |
|
779 benzylamine antifungal [epc] |
|
780 benzylamines [chemical/ingredient] |
|
781 cystine depleting agent [epc] |
|
782 local anesthetic [epc] |
|
783 contrast agent for ultrasound imaging [epc] |
|
784 ultrasound contrast activity [moa] |
|
785 lipopeptide antibacterial [epc] |
|
786 adenosine receptor agonist [epc] |
|
787 adenosine receptor agonists [moa] |
|
788 partial opioid agonist/antagonist [epc] |
|
789 dopaminergic agonist [epc] |
|
790 antidote [epc] |
|
791 antidote for acetaminophen overdose [epc] |
|
792 decreased respiratory secretion viscosity [pe] |
|
793 increased glutathione concentration [pe] |
|
794 mucolytic [epc] |
|
795 reduction activity [moa] |
|
796 copper absorption inhibitor [epc] |
|
797 decreased copper ion absorption [pe] |
|
798 depolarizing neuromuscular blocker [epc] |
|
799 neuromuscular depolarizing blockade [pe] |
|
800 tetracycline-class antimicrobial [epc] |
|
801 guanylate cyclase-c agonist [epc] |
|
802 guanylate cyclase activators [moa] |
|
803 beta3-adrenergic agonist [epc] |
|
804 adrenergic beta3-agonists [moa] |
|
805 lipid-based polyene antifungal [epc] |
|
806 decreased mitosis [pe] |
|
807 tubulin inhibiting agent [epc] |
|
808 pyrethrins [chemical/ingredient] |
|
809 pyrethroid [epc] |
|
810 arteriolar vasodilation [pe] |
|
811 arteriolar vasodilator [epc] |
|
812 carnitine [chemical/ingredient] |
|
813 carnitine analog [epc] |
|
814 cholinergic muscarinic agonist [epc] |
|
815 adrenocorticotropic hormone [chemical/ingredient] |
|
816 adrenocorticotropic hormone [epc] |
|
817 endoglycosidase [epc] |
|
818 glycoside hydrolases [chemical/ingredient] |
|
819 human immunoglobulin g [epc] |
|
820 passively acquired immunity [pe] |
|
821 endogenous antigen neutralization [moa] |
|
822 uncompetitive n-methyl-d-aspartate receptor antagonist [epc] |
|
823 sigma-1 agonist [epc] |
|
824 uncompetitive nmda receptor antagonists [moa] |
|
825 sigma-1 receptor agonists [moa] |
|
826 antihypoglycemic agent [epc] |
|
827 gastrointestinal motility inhibitor [epc] |
|
828 increased gluconeogenesis [pe] |
|
829 increased glycogenolysis [pe] |
|
830 decreased gi smooth muscle tone [pe] |
|
831 decreased gi motility [pe] |
|
832 decreased glycolysis [pe] |
|
833 humanized monoclonal antibody fragment [epc] |
|
834 monoclonal |
|
835 humanized [chemical/ingredient] |
|
836 vitamin a [chemical/ingredient] |
|
837 vitamin a [epc] |
|
838 increased medullary respiratory drive [pe] |
|
839 respiratory stimulant [epc] |
|
840 copper [chemical/ingredient] |
|
841 copper-containing intrauterine device [epc] |
|
842 decreased embryonic implantation [pe] |
|
843 decreased sperm motility [pe] |
|
844 autonomic ganglionic blocker [epc] |
|
845 decreased autonomic ganglionic activity [pe] |
|
846 antigen neutralization [moa] |
|
847 human alpha-1 proteinase inhibitor [epc] |
|
848 trypsin inhibitors [moa] |
|
849 asparaginase [chemical/ingredient] |
|
850 asparagine-specific enzyme [epc] |
|
851 5-lipoxygenase inhibitor [epc] |
|
852 5-lipoxygenase inhibitors [moa] |
|
853 decreased leukotriene production [pe] |
|
854 potassium channel blocker [epc] |
|
855 glucosylceramide synthase inhibitor [epc] |
|
856 glucosylceramide synthase inhibitors [moa] |
|
857 oxaborole antifungal [epc] |
|
858 boron compounds [chemical/ingredient] |
|
859 cholinesterase reactivator [epc] |
|
860 cholinesterase reactivators [moa] |
|
861 inhalation diagnostic agent [epc] |
|
862 inactivated clostridium tetani vaccine [epc] |
|
863 tetanus toxoid [chemical/ingredient] |
|
864 inactivated corynebacterium diphtheriae vaccine [epc] |
|
865 diphtheria toxoid [chemical/ingredient] |
|
866 human immunoglobulin [epc] |
|
867 virus neutralization [moa] |
|
868 virus-specific hyperimmune globulins [chemical/ingredient] |
|
869 norepinephrine releasing agent [epc] |
|
870 pleuromutilin [chemical/ingredient] |
|
871 pleuromutilin antibacterial [epc] |
|
872 chloride channel activator [epc] |
|
873 chloride channel activators [moa] |
|
874 bee venoms [chemical/ingredient] |
|
875 standardized insect venom allergenic extract [epc] |
|
876 radioactive therapeutic agent [epc] |
|
877 increased prostaglandin activity [pe] |
|
878 n-calcium channel receptor antagonists [moa] |
|
879 n-type calcium channel antagonist [epc] |
|
880 melatonin receptor agonist [epc] |
|
881 melatonin receptor agonists [moa] |
|
882 demulcent [epc] |
|
883 demulcent activity [moa] |
|
884 proteolytic enzyme [epc] |
|
885 peptide hydrolases [chemical/ingredient] |
|
886 catecholamine synthesis inhibitor [epc] |
|
887 catecholamine synthesis inhibitors [moa] |
|
888 complement inhibitor [epc] |
|
889 complement inhibitors [moa] |
|
890 hydrolytic lysosomal cholesteryl ester-specific enzyme [epc] |
|
891 hydrolytic lysosomal triacylglycerol-specific enzyme [epc] |
|
892 lysosomal acid cholesterol esterase [chemical/ingredient] |
|
893 tissue-nonspecific alkaline phosphatase [epc] |
|
894 alkaline phosphatase [chemical/ingredient] |
|
895 autologous cellular immunotherapy [epc] |
|
896 cultured |
|
897 autologous [chemical/ingredient] |
|
898 peripheral blood mononuclear cells [chemical/ingredient] |
|
899 vesicular monoamine transporter 2 inhibitor [epc] |
|
900 vesicular monoamine transporter 2 inhibitors [moa] |
|
901 inactivated influenza a virus vaccine [epc] |
|
902 influenza vaccines [chemical/ingredient] |
|
903 silk [chemical/ingredient] |
|
904 skin test antigen [epc] |
|
905 tuberculosis skin test [epc] |
|
906 bacterial [chemical/ingredient] |
|
907 human c1 esterase inhibitor [epc] |
|
908 decreased vascular permeability [pe] |
|
909 kallikrein inhibitors [moa] |
|
910 interferon gamma [epc] |
|
911 interferon-gamma [chemical/ingredient] |
|
912 inactivated japanese encephalitis virus vaccine [epc] |
|
913 japanese encephalitis vaccines [chemical/ingredient] |
|
914 allogeneic cultured cell scaffold [epc] |
|
915 collagen [chemical/ingredient] |
|
916 tissue scaffolds [chemical/ingredient] |
|
917 allogeneic [chemical/ingredient] |
|
918 fibroblasts [chemical/ingredient] |
|
919 keratinocytes [chemical/ingredient] |
|
920 recombinant antithrombin [epc] |
|
921 anti-anginal [epc] |
|
922 live attenuated influenza a virus vaccine [epc] |
|
923 interferon-beta [chemical/ingredient] |
|
924 recombinant human interferon beta [epc] |
|
925 recombinant proteins [chemical/ingredient] |
|
926 parathyroid hormone [epc] |
|
927 sclerosing agent [epc] |
|
928 sclerosing activity [moa] |
|
929 vascular sclerosing activity [pe] |
|
930 plasma kallikrein inhibitor [epc] |
|
931 inactivated bordetella pertussis vaccine [epc] |
|
932 pertussis vaccine [chemical/ingredient] |
|
933 inactivated poliovirus vaccine [epc] |
|
934 poliovirus vaccine [chemical/ingredient] |
|
935 inactivated meningococcal vaccine [epc] |
|
936 meningococcal vaccines [chemical/ingredient] |
|
937 inactivated salmonella typhi vaccine [epc] |
|
938 typhoid [chemical/ingredient] |
|
939 vi polysaccharide vaccine |
|
940 live attenuated yellow fever virus vaccine [epc] |
|
941 yellow fever vaccine [chemical/ingredient] |
|
942 non-standardized bacterial allergenic extract [epc] |
|
943 bacterial proteins [chemical/ingredient] |
|
944 non-standardized animal hair allergenic extract [epc] |
|
945 decreased b lymphocyte activation [pe] |
|
946 b lymphocyte stimulator-specific inhibitor [epc] |
|
947 b lymphocyte stimulator-directed antibody interactions [moa] |
|
948 anthrax protective antigen-directed antibody [epc] |
|
949 anthrax protective antigen-directed antibody interactions [moa] |
|
950 multidrug and toxin extrusion transporter 1 inhibitors [moa] |
|
951 methylated sulfonamide antibacterial [epc] |
|
952 methylated sulfonamides [chemical/ingredient] |
|
953 selective progesterone receptor modulators [moa] |
|
954 progesterone agonist/antagonist [epc] |
|
955 live vaccinia virus vaccine [epc] |
|
956 smallpox vaccine [chemical/ingredient] |
|
957 cell death inducer [epc] |
|
958 anti-ige [epc] |
|
959 decreased ige activity [pe] |
|
960 ige-directed antibody interactions [moa] |
|
961 vascular endothelial growth factor receptor inhibitors [moa] |
|
962 vascular endothelial growth factor-directed antibody [epc] |
|
963 vascular endothelial growth factor-directed antibody interactions [moa] |
|
964 deoxyribonuclease i [chemical/ingredient] |
|
965 recombinant human deoxyribonuclease 1 [epc] |
|
966 pyridone [epc] |
|
967 pyridones [chemical/ingredient] |
|
968 her2 receptor antagonist [epc] |
|
969 her2/neu/cerbb2 antagonists [moa] |
|
970 antibodies [chemical/ingredient] |
|
971 radioactive alpha-particle emitting therapeutic agent [epc] |
|
972 alpha-particle emitting activity [moa] |
|
973 guanylate cyclase stimulators [moa] |
|
974 soluble guanylate cyclase stimulator [epc] |
|
975 antihelminthic [epc] |
|
976 glycosaminoglycan [epc] |
|
977 glycosaminoglycans [chemical/ingredient] |
|
978 epoxide hydrolase inhibitors [moa] |
|
979 collagenases [chemical/ingredient] |
|
980 collagen-specific enzyme [epc] |
|
981 human platelet-derived growth factor [epc] |
|
982 platelet-derived growth factor [chemical/ingredient] |
|
983 antivenin [epc] |
|
984 venom neutralization [moa] |
|
985 antivenins [chemical/ingredient] |
|
986 carboxypeptidase [epc] |
|
987 carboxypeptidases [chemical/ingredient] |
|
988 cd30-directed antibody interactions [moa] |
|
989 cd30-directed immunoconjugate [epc] |
|
990 immunoconjugates [chemical/ingredient] |
|
991 cystic fibrosis transmembrane conductance regulator potentiator [epc] |
|
992 chloride channel activation potentiators [moa] |
|
993 lead chelating activity [moa] |
|
994 lead chelator [epc] |
|
995 macrolide antibacterial [epc] |
|
996 cytochrome p450 1a inducers [moa] |
|
997 lipoglycopeptide antibacterial [epc] |
|
998 lipoglycopeptides [chemical/ingredient] |
|
999 carbamoyl phosphate synthetase 1 activator [epc] |
|
1000 carbamoyl phosphate synthetase 1 activators [moa] |
|
1001 methylating activity [moa] |
|
1002 methylating agent [epc] |
|
1003 wasp venoms [chemical/ingredient] |
|
1004 potassium binder [epc] |
|
1005 potassium ion binding activity [moa] |
|
1006 calcium-sensing receptor agonist [epc] |
|
1007 increased calcium-sensing receptor sensitivity [moa] |
|
1008 lymphocyte function-associated antigen-1 antagonist [epc] |
|
1009 lymphocyte function-associated antigen-1 antagonists [moa] |
|
1010 alpha-glucosidases [chemical/ingredient] |
|
1011 hydrolytic lysosomal glycosaminoglycan-specific enzyme [epc] |
|
1012 bradykinin b2 receptor antagonist [epc] |
|
1013 bradykinin b2 receptor antagonists [moa] |
|
1014 urate oxidase [chemical/ingredient] |
|
1015 uric acid-specific enzyme [epc] |
|
1016 aromatic amino acid decarboxylation inhibitor [epc] |
|
1017 dopa decarboxylase inhibitors [moa] |
|
1018 ketolide antibacterial [epc] |
|
1019 ketolides [chemical/ingredient] |
|
1020 heparin binding activity [moa] |
|
1021 heparin reversal agent [epc] |
|
1022 actinomycin [epc] |
|
1023 free radical scavenging activity [moa] |
|
1024 rank ligand inhibitor [epc] |
|
1025 rank ligand blocking activity [moa] |
|
1026 hyperpolarization-activated cyclic nucleotide-gated channel blocker [epc] |
|
1027 hyperpolarization-activated cyclic nucleotide-gated channel antagonists [moa] |
|
1028 adenosine deaminase [chemical/ingredient] |
|
1029 bovine intestinal adenosine deaminase [epc] |
|
1030 interleukin-12 antagonist [epc] |
|
1031 interleukin-12 antagonists [moa] |
|
1032 interleukin-23 antagonist [epc] |
|
1033 interleukin-23 antagonists [moa] |
|
1034 cytochrome p450 17a1 inhibitors [moa] |
|
1035 cytochrome p450 17a1 inhibitor [epc] |
|
1036 interleukin-6 antagonist [epc] |
|
1037 interleukin-6 antagonists [moa] |
|
1038 cd38-directed cytolytic antibody [epc] |
|
1039 cd38-directed antibody interactions [moa] |
|
1040 decorporation agent [epc] |
|
1041 ion exchange activity [moa] |
|
1042 chelating activity [moa] |
|
1043 thyroid stimulating hormone [epc] |
|
1044 thyrotropin [chemical/ingredient] |
|
1045 hydrolytic lysosomal neutral glycosphingolipid-specific enzyme [epc] |
|
1046 hydrolytic lysosomal glycogen-specific enzyme [epc] |
|
1047 apolipoprotein b-100 synthesis inhibitor [epc] |
|
1048 antisense oligonucleotide [epc] |
|
1049 oligonucleotides |
|
1050 antisense [chemical/ingredient] |
|
1051 cd52-directed antibody interactions [moa] |
|
1052 cd52-directed cytolytic antibody [epc] |
|
1053 pyrimidine synthesis inhibitor [epc] |
|
1054 dihydroorotate dehydrogenase inhibitors [moa] |
|
1055 autologous cultured cell [epc] |
|
1056 chondrocytes [chemical/ingredient] |
|
1057 bismuth [chemical/ingredient] |
|
1058 bismuth [epc] |
|
1059 vasopressin v2 receptor antagonist [epc] |
|
1060 vasopressin v2 receptor antagonists [moa] |
|
1061 decreased immunologically active molecule activity [pe] |
|
1062 thalidomide analog [epc] |
|
1063 fungal [chemical/ingredient] |
|
1064 cd3 blocker immunosuppressant [epc] |
|
1065 cd3 receptor antagonists [moa] |
|
1066 cd3-directed antibody interactions [moa] |
|
1067 diarylquinoline antimycobacterial [epc] |
|
1068 diarylquinolines [chemical/ingredient] |
|
1069 fusion protein inhibitors [moa] |
|
1070 respiratory syncytial virus anti-f protein monoclonal antibody [epc] |
|
1071 angiotensin 2 type 1 receptor antagonists [moa] |
|
1072 cytolytic agent [epc] |
|
1073 decreased cell membrane integrity [pe] |
|
1074 streptogramin antibacterial [epc] |
|
1075 streptogramins [chemical/ingredient] |
|
1076 antileishmanial [epc] |
|
1077 mu-opioid receptor agonist [epc] |
|
1078 opioid mu-receptor agonists [moa] |
|
1079 endothelin receptor antagonist [epc] |
|
1080 endothelin receptor antagonists [moa] |
|
1081 hepatitis c virus nucleotide analog ns5b polymerase inhibitor [epc] |
|
1082 rna replicase inhibitors [moa] |
|
1083 organic anion transporting polypeptide 2b1 inhibitors [moa] |
|
1084 noncompetitive ampa glutamate receptor antagonist [epc] |
|
1085 ampa receptor antagonists [moa] |
|
1086 serotonin-2c receptor agonist [epc] |
|
1087 serotonin 2c receptor agonists [moa] |
|
1088 proteasome inhibitor [epc] |
|
1089 proteasome inhibitors [moa] |
|
1090 amphenicol-class antibacterial [epc] |
|
1091 amphenicols [chemical/ingredient] |
|
1092 deoxyuridine [chemical/ingredient] |
|
1093 integrin receptor antagonist [epc] |
|
1094 integrin receptor antagonists [moa] |
|
1095 survival motor neuron-2-directed rna interaction [epc] |
|
1096 increased protein synthesis [pe] |
|
1097 live attenuated bacillus anthracis vaccine [epc] |
|
1098 anthrax vaccines [chemical/ingredient] |
|
1099 thymidine phosphorylase inhibitor [epc] |
|
1100 thymidine phosphorylase inhibitors [moa] |
|
1101 non-standardized animal dander allergenic extract [epc] |
|
1102 increased lymphocyte activation [pe] |
|
1103 increased lymphocyte cell production [pe] |
|
1104 interleukin-2 [chemical/ingredient] |
|
1105 lymphocyte growth factor [epc] |
|
1106 quaternary ammonium compounds [chemical/ingredient] |
|
1107 natriuretic peptide [epc] |
|
1108 natriuretic peptides [chemical/ingredient] |
|
1109 prostacycline [epc] |
|
1110 prostacyclin receptor agonist [epc] |
|
1111 prostacyclin receptor agonists [moa] |
|
1112 vasopressin receptor antagonists [moa] |
|
1113 vasopressin receptor antagonist [epc] |
|
1114 glycolipid disialoganglioside-directed antibody [epc] |
|
1115 glycolipid disialoganglioside-directed antibody interactions [moa] |
|
1116 hydroxyphenyl-pyruvate dioxygenase inhibitor [epc] |
|
1117 hydroxyphenylpyruvate dioxygenase inhibitors [moa] |
|
1118 fibroblast growth factor 7 [chemical/ingredient] |
|
1119 increased epithelial proliferation [pe] |
|
1120 mucocutaneous epithelial cell growth factor [epc] |
|
1121 interleukin 1 receptor antagonists [moa] |
|
1122 interleukin-1 receptor antagonist [epc] |
|
1123 increased blood pressure [pe] |
|
1124 human antihemophilic factor [epc] |
|
1125 factor viii [chemical/ingredient] |
|
1126 increased platelet aggregation [pe] |
|
1127 von willebrand factor [chemical/ingredient] |
|
1128 sucrose-specific enzyme [epc] |
|
1129 phenylalanine hydroxylase activator [epc] |
|
1130 bacterial neurotoxin neutralization [moa] |
|
1131 antitoxins [chemical/ingredient] |
|
1132 central nervous system depressant [epc] |
|
1133 decreased central nervous system organized electrical activity [pe] |
|
1134 oligonucleotides [chemical/ingredient] |
|
1135 aptamers |
|
1136 nucleotide [chemical/ingredient] |
|
1137 glp-2 analog [epc] |
|
1138 glucagon-like peptide-2 (glp-2) agonists [moa] |
|
1139 glucagon-like peptide 2 [chemical/ingredient] |
|
1140 live attenuated salmonella typhi vaccine [epc] |
|
1141 pyrimidine analog [epc] |
|
1142 pyrimidines [chemical/ingredient] |
|
1143 farnesoid x receptor agonist [epc] |
|
1144 farnesoid x receptor agonists [moa] |
|
1145 inactivated influenza b virus vaccine [epc] |
|
1146 porphyrin precursor [epc] |
|
1147 porphyrinogens [chemical/ingredient] |
|
1148 fluoroquinolone antibacterial [epc] |
|
1149 fluoroquinolones [chemical/ingredient] |
|
1150 pyrophosphate analog [chemical/ingredient] |
|
1151 pyrophosphate analog dna polymerase inhibitor [epc] |
|
1152 adrenal steroid synthesis inhibitor [epc] |
|
1153 adrenal steroid synthesis inhibitors [moa] |
|
1154 progestational hormone receptor antagonists [moa] |
|
1155 progestin antagonist [epc] |
|
1156 microsomal triglyceride transfer protein inhibitor [epc] |
|
1157 microsomal triglyceride transfer protein inhibitors [moa] |
|
1158 leptin analog [epc] |
|
1159 leptin [chemical/ingredient] |
|
1160 allogeneic cord blood hematopoietic progenitor cell therapy [epc] |
|
1161 hematopoietic stem cells [chemical/ingredient] |
|
|